J N Allen Selected Research

Therapeutics

7/2014	Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
1/2014	Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J N Allen Research Topics

Disease

2	Rectal Neoplasms (Rectal Cancer) 01/2017 - 01/2014
2	Pathologic Complete Response 01/2017 - 01/2014
1	Gallbladder Neoplasms (Gallbladder Cancer) 07/2014
1	Adenocarcinoma 07/2014
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 07/2014
1	Critical Illness (Critically Ill) 03/2001

Drug/Important Bio-Agent (IBA)

1	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2014
1	Panitumumab (Vectibix)FDA Link 07/2014
1	PlatinumIBA 07/2014
1	Gemcitabine FDA Link 07/2014
1	Bevacizumab (Avastin)FDA Link 01/2014
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2014
1	Fluorouracil (Carac)FDA LinkGeneric 01/2014

Therapy/Procedure

2	Therapeutics 07/2014 - 01/2014
1	Neoadjuvant Therapy 01/2017
1	Radiotherapy 01/2014
1	Airway Management 03/2001